Early trial explores new drug for blood cancers in japanese patients

NCT ID NCT05673460

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The main goals were to check the drug's safety and how the body processes it. Researchers looked for side effects and measured drug levels in the blood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia lymphoplasmacytic lymphoma neoplasm of mature B-cells Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chiba Cancer Center ( Site 0005)

    Chiba, 260-8717, Japan

  • Kindai University Hospital ( Site 0006)

    Sayama, Osaka, 589-8511, Japan

  • Kyushu University Hospital ( Site 0008)

    Fukuoka, 812-8582, Japan

  • Nagoya University Hospital ( Site 0003)

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital East ( Site 0002)

    Kashiwa, Chiba, 2778577, Japan

  • Okayama University Hospital ( Site 0007)

    Okayama, 700-8558, Japan

  • Yamagata University Hospital ( Site 0001)

    Yamagata, 990-9585, Japan